source
- Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten reboundTwenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021, when the industry recorded 78 during the hei…
- Bristol Myers Squibb ends partnership with Cellares, prompting the cell therapy maker to restructureBristol Myers Squibb announced that it is terminating its collaboration with Cellares after completing a comprehensive evaluation of the partnership. The decision was driven by BMS’s assessment th…